Glucagon-Like Peptide-1 (GLP-1) Metabolism in the Setting of Acute Neprilysin Inhibition

Brief Description Of Study

The purpose of this study is to determine if the medicine sacubitril/ valsartan will raise levels of the hormone glucagon-like peptide-1 (GLP-1) after a meal that may be beneficial for controlling blood sugar. We are also measuring if this pill will lower triglycerides. A large percent of people with high blood pressure also have pre-diabetes or diabetes and risk of heart disease so learning more about its effects related to blood sugar and cholesterol lowering is important. All of the medications used in the study have been approved by the Food and Drug Administration (FDA). Valsartan is used for the treatment of high blood pressure. Sacubitril/ valsartan is approved for use in patients with heart failure with reduced ejection fraction (decreased ability of the heart to pump blood out effectively). It has also been studied in people with high blood pressure without heart failure, although it is not FDA approved for this indication at this time. The use of sacubitril/valsartan in this study is investigational.

Clinical Study Identifier: NCT03508739

Detailed Study Description

To test if sacubitril/valsartan raises GLP-1 levels (and improves insulin and glucose after a meal) compared to valsartan, you will receive one of each of these medications on study day 2 and 3 in random order. The study days will be identical with the exception of which medication you receive. You will be asked to participate in the study for approximately 5 weeks. It may be for a shorter period if you do not need to washout from any of your current medications. If you choose to participate, you will be compensated a total of $225 for completing the 3 study days. Identifier: NCT03508739

Check eligibility to participate in the study

We'll show you investigators/research sites in this zip.

You are eligible for this study


Select Investigators or Research Sites to contact


Send Message to Investigator

Enter your First name
Enter your Last name

This email is already registered for this trial.

Your email helps investigators to follow up with you.
Your phone number helps investigators to follow up with you.
Preview Message
Click to see the preview of your message

Message successfuly sent.

Your message to participate in the study has been sent to the investigator(s). For your record, we've sent a copy of your message to your email. We'll notify you when the investigator replies. You also may be called shortly by a clinical trial personnel to ask you more questions.